# US 2021/0276990 A1 · 5-[[4-[[Morpholin-2-yl]Methylamino]-5-(Trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-Carbonitrile and Therapeutic Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0276990 A1
- Document ID: US20210276990A1
- Status: Published application
- Kind: A1
- Application number: 17/124,606
- Filed: 2020-12-17
- Published: 2021-09-09
- Earliest claimed: 2012-05-15
- Assignees: Cancer Research Technology Limited
- Applicants: Cancer Research Technology Limited
- Inventors: Ian Collins; Thomas Peter Matthews; Tatiana Faria Da Fonseca McHardy; James Osborne; Michael Lainchbury; Michael Ian Walton; Michelle Dawn Garrett
- Web page: https://patentgrep.com/patent/US20210276990A1

## CPC

- C07D 413/14: containing three or more hetero rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 413/02: containing two hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to herein as “TFM compounds”) which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionising radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; or (h) an inhibitor of a DNA damage repair enzyme.

## Claims

### Claim at position 1

-66. (canceled)

### Claim 67

A kit comprising
(a) a therapeutically-effective amount of a TFM compound in a suitable container, wherein the TFM compound is a compound of the following formula, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:
and
(b) instructions for use.

### Claim 68 (depends on 67)

The kit of claim 67, wherein the instructions comprise written instructions on how to administer the TFM compound.

### Claim 69 (depends on 67)

The kit of claim 67, wherein the TFM compound is a compound of the following formula, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:

### Claim 70 (depends on 67)

The kit of claim 67, wherein the TFM compound is a compound of the following formula, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:

### Claim 71 (depends on 67)

The kit of claim 67, wherein the TFM compound is provided in a pharmaceutical composition comprising the TFM compound and a pharmaceutically acceptable carrier or diluent.

### Claim 72 (depends on 71)

The kit of claim 71, wherein the pharmaceutical composition is suitable for oral administration to a subject.

### Claim 73 (depends on 67)

The kit of claim 67, further comprising a therapeutically-effective amount of one or more other agents provided in suitable containers, wherein the agents are chosen from: (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) a systemic radiopharmaceutical; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; and (h) an inhibitor of a DNA damage repair enzyme.

### Claim 74 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating a disease or condition that is mediated by CHK1

### Claim 75 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating a disease or condition that is ameliorated by the inhibition of CHK1 kinase function.

### Claim 76 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating a proliferative condition.

### Claim 77 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating cancer.

### Claim 78 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating head cancer; neck cancer; nervous system cancer; brain cancer; neuroblastoma; lung/mediastinum cancer; breast cancer; oesophagus cancer; stomach cancer; liver cancer; biliary tract cancer; pancreatic cancer; small bowel cancer; large bowel cancer; colorectal cancer; gynaecological cancer; genito-urinary cancer; ovarian
cancer; thyroid gland cancer; adrenal gland cancer; skin cancer; melanoma; bone sarcoma; soft tissue sarcoma; paediatric malignancy; Hodgkin's disease; non-Hodgkin's lymphoma; myeloma; leukaemia; or metastasis from an unknown primary site.

### Claim 79 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating lung cancer, breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, melanoma, glioma, or neuroblastoma.

### Claim 80 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating MYC-amplified cancer.

### Claim 81 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating c-MYC-amplified cancer.

### Claim 82 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating MYCN-amplified cancer.

### Claim 83 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating cancer characterised by overexpression of MYC.

### Claim 84 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating cancer characterised by overexpression of MYCN.

### Claim 85 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating cancer characterised by overexpression of c-MYC.

### Claim 86 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating MYCN-amplified neuroblastoma.

### Claim 87 (depends on 67)

The kit of claim 67, wherein the kit comprises instructions for treating c-MYC-amplified B cell lymphoma.
